Full Press Release Details
LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR ) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30 , on Thursday, August 3, 2023 .
Pharming will host a presentation for analysts and investors at 13:30 CEST / 07:30 EDT on August 3, 2023 .
Dial in details for the presentation are detailed below.
Webcast Link: https://webcast.openbriefing.com/pharming1h23/
Conference Call Dial-in Details: Netherlands : +31 85 888 7233 United States (Local): +1 646 664 1960 United Kingdom (Local): +44 20 3936 2999 Global Dial-In Numbers Access Code: 760288
About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR ) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands , and has employees around the globe who serve patients in over 30 markets in North America , Europe , the Middle East , Africa , and Asia-Pacific .
For more information, visit www.pharming.com and find us on LinkedIn .
For further public information, contact:
Pharming Group, Leiden, The Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696
Heather Robertson , Investor Relations & Corporate Communications Manager E: investor@pharming. com